Global Depression Screening Market Research Report - Forecast to 2023

According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015.

Reference: 180164
Price: $4,450.00
Tax included

General

Geography Covered
Global
Publisher:
Market Research Future
Publication Date
17-Dec-17
Pages
101
Language
  • English
Format
License

Depression and mental health are the leading cause of disability and ill health across the globe. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness
The market for depression screening by disease type is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and other mental and behavioral & disorders, in which the anxiety market accounted for the largest market share in 2016 due to growing social and environmental variations, and changing lifestyle among the working class across the globe.
The depression screening market is further segmented into diagnosis. These diagnosis are further segmented into psychological test, lab tests, depression screening tests and others. Global depression screening market by diagnosis is expected to reach USD 1,648.98 million by 2023.
Further, the market is segmented on the basis of treatment, which includes medications, brain-stimulation treatments, substance abuse treatment and others. Medications is one of the main treatment for the depression screening market.
Additionally, the market is further segmented on the basis of end user and is bifurcated into hospitals & clinics, medical research centers, academic institutes and others. Out of which hospitals & clinics holds the largest market share among the all the end users.
On the basis of region the market is segmented into America, Europe, Asia-Pacific and Middle East and Africa. Globally Americas holds the largest market share in 2016 due to various factors such as availability advanced diagnostic and treatment, funding for research, increasing number of patients with mental illness and related disorders.
Key Players
Some of the key players in this market are Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.
Study objectives
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on disease type, diagnosis, end user and regions for the global depression screening market
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economical factors that influences the global depression screening market
• To provide detailed analysis of the value chain and supply chain of the global depression screening market
Target Audience
• Pharmaceutical and Biotech Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• Global market for depression screening is majorly dominated by six companies namely Pfizer, Eli Lilly, Allergan, Alkermes, AstraZeneca, Novartis, Bristol-Myers Squibb Company and Others. Eli Lilly takes about 26% of the total market
• On the basis of level of treatment antidepressants is the fastest growing market
• Currently, anxiety is leading the market by disease type as anxiety disorders are the most common of all the mental disorders and affects nearly 30% of adults at some point in their lives.
• The market is growing with an equitable pace of 6.20% annually. Growing emergence of digital health technologies in mental health, rising prevalence of mental disorders across the globe, new focus area in the care continuum has up surged the growth of the market
The reports also covers regional analysis
• Americas
o U.S.
o Canada
o South America
• Europe
o Germany
o France
o U.K
o Italy
o Spain
o Rest of Western Europe
o Eastern Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

 

Table of Contents

1 Report Prologue 12
2 Market Introduction 16
2.1 Scope of Study 16
2.2 Research Objective 16
2.3 Assumptions & Limitations 16
2.3.1 Assumptions 16
2.3.2 Limitations 16
3 Research Methodology 17
3.1 Primary Research Methodology 18
3.2 Secondary Research Methodology 19
3.3 Market Share Analysis 20
3.4 Trade Analysis 20
3.5 Market Pricing Approach 20
4 Market Dynamics 21
4.1 Introduction 21
4.2 Drivers 22
4.2.1 Emergence of digital health technologies in mental health
(Impact weightage-45%) 22
4.2.2 Growing prevalence of mental disorders around the globe
(Impact weightage-30%) 23
4.2.3 New focus areas in the care continuum are prevention and recovery
(Impact weightage-25%) 24
4.3 Restraints 25
4.3.1 Low public awareness of mental disorders and treatments in emerging nations (Impact weightage-55%) 25
4.3.2 Cultural Stigma preventing the market growth (Impact weightage-45%) 26
5 Market Factor Analysis 27
5.1 Porter’s Five Forces Model 27
5.1.1 Bargaining Power of Suppliers 28
5.1.2 Bargaining Power of Buyers 28
5.1.3 Threat of New Entrants 28
5.1.4 Threat of Substitutes 28
5.1.5 Intensity of Rivalry 28
5.2 Value Chain Analysis 29

6 Global Depression Screening Market, By Disease Type 30
6.1 Introduction 30
6.2 Anxiety 32
6.3 Mood Disorders 32
6.4 Depression 33
6.5 Bipolar Disorders 33
6.6 Psychotic Disorders 34
6.7 Eating Disorders 34
7 Global Depression Screening Market, By Diagnosis 35
7.1 Introduction 35
7.2 Psychological Test 36
7.3 Lab Tests 37
7.4 Depression Screening Tests 37
8 Global Depression Screening Market, By Treatment 38
8.1 Introduction 38
8.2 Medication 40
8.3 Brain-Stimulation Treatments 40
8.4 Substance Abuse Treatment 41
9 Global Depression Screening Market, By End User 42
9.1 Introduction 42
9.2 Hospitals & Clinics 43
9.3 Medical Research Centers 43
9.4 Academic Institutes 44
10 Global Depression Screening Market, By Region 45
10.1 Introduction 45
10.2 Americas 46
10.2.1 U.S. 49
10.2.2 Canada 51
10.2.3 South America 53
10.3 Europe 55
10.3.1 Germany 58
10.3.2 France 60
10.3.3 UK 62
10.3.4 Italy 64
10.3.5 Spain 66
10.3.6 Rest of Western Europe 68
10.3.7 Eastern Europe 70

10.4 Asia Pacific 72
10.4.1 Japan 75
10.4.2 China 77
10.4.3 India 79
10.4.4 Australia 81
10.4.5 Republic of Korea 83
10.4.6 Rest of Asia Pacific 85
10.5 Middle East & Africa 87
10.5.1 Middle East 90
10.5.2 Africa 92
11 Company Share Analysis 94
12 Company Profiles: Top 7 Players 95
12.1 Allergan 95
12.1.1 Company Overview 95
12.1.2 Financials 95
12.1.3 Products 95
12.1.4 Strategy 95
12.1.5 Key Developments 95
12.2 Eli Lilly 96
12.2.1 Company Overview 96
12.2.2 Financials 96
12.2.3 Products 96
12.2.4 Strategy 96
12.2.5 Key Developments 96
12.3 Novartis AG. 97
12.3.1 Company Overview 97
12.3.2 Financials 97
12.3.3 Products 97
12.3.4 Strategy 97
12.3.5 Key Developments 97
12.4 Alkermes 98
12.4.1 Company Overview 98
12.4.2 Financials 98
12.4.3 Products 98
12.4.4 Strategy 98
12.4.5 Key Developments 98
12.5 Bristol-Myers Squibb Company 99
12.5.1 Company Overview 99
12.5.2 Financials 99
12.5.3 Products 99
12.5.4 Strategy 99
12.5.5 Key Developments 99
12.6 Pfizer 100
12.6.1 Company Overview 100
12.6.2 Financials 100
12.6.3 Products 100
12.6.4 Strategy 100
12.6.5 Key Developments 100

 

Scroll